ImmuronIMRN
About: Immuron Ltd is a commercial and clinical-stage biopharmaceutical company focused on the development and commercialization of a novel class of immunomodulator polyclonal antibodies to treat liver diseases, infectious diseases and other immune-mediated diseases, such as colitis. The company's product, IMM-124E, is a proprietary immunomodulatory agent targeted at GI immune-mediated diseases including fatty liver diseases. The company functions in two segments namely, Research and Development and Hyperimmune products.
Employees: 7
Fund manager confidence
Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)
0% less ownership
Funds ownership: 0% [Q3] → 0% (-0%) [Q4]
64% less capital invested
Capital invested by funds: $29.2K [Q3] → $10.5K (-$18.8K) [Q4]
67% less funds holding
Funds holding: 3 [Q3] → 1 (-2) [Q4]
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 2
Research analyst outlook
We haven’t received any recent analyst ratings for IMRN.
Financial journalist opinion









